Ten63 Therapeutics
Durham, US · Founded 2019 · Delaware corporation · 4 known investors
Ten63 develops drug-discovery technology that combines generative chemistry with quantum-accurate molecular simulation, including BEYOND (a large quantum chemistry model) and Sentinel (a virtual CSO for target selection), to design therapeutics against previously undruggable targets. It runs an internal pipeline of first-in-class and best-in-class programs across oncology and other serious diseases.
AI & Machine LearningBiotechDeep Tech
Founders & leadership
MF
Marcel FrenkelExecutive Officer, Director
MA
Mark A. HallenExecutive Officer, Director
DP
Damien PettyDirector
JW
Jia Wei XuDirector
Investors · 4
Reported raises · per SEC filings
Form D private placements▶$2.1MraisedJan 2021 · 7 investors · OtherRule 506(b)
▶$2.1MraisedJan 2021 · 7 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Marcel FrenkelExecutive Officer, Director
- Mark A. HallenExecutive Officer, Director
- Damien PettyDirector
- Jia Wei XuDirector
- Offering amount
- $2.1M
- Amount sold
- $2.1M
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.